Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Multiple Sclerosis

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 234 articles:
HTML format



Single Articles


    May 2020
  1. MANOUCHEHRINIA A, Stridh P, Khademi M, Leppert D, et al
    Plasma neurofilament light levels are associated with the risk of disability in multiple sclerosis.
    Neurology. 2020 May 20. pii: WNL.0000000000009571.
    PubMed     Abstract available


  2. LANDMEYER NC, Burkner PC, Wiendl H, Ruck T, et al
    Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
    Neurology. 2020 May 19. pii: WNL.0000000000009522.
    PubMed     Abstract available


    April 2020
  3. ARUN T, Pattison L, Palace J
    Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: A retrospective cohort study.
    Neurology. 2020 Apr 30. pii: WNL.0000000000009491.
    PubMed     Abstract available


  4. LANGER-GOULD A, Smith JB, Albers KB, Xiang AH, et al
    Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort.
    Neurology. 2020 Apr 13. pii: WNL.0000000000009374.
    PubMed     Abstract available


  5. DOBSON R, Mowry EM
    Breastfeeding may reduce postpartum relapse in some women with multiple sclerosis.
    Neurology. 2020 Apr 13. pii: WNL.0000000000009369.
    PubMed    


  6. BROWNLEE W, Bourdette D, Broadley S, Killestein J, et al
    Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
    Neurology. 2020 Apr 2. pii: WNL.0000000000009507.
    PubMed     Abstract available


    March 2020
  7. TINTORE M, Perez-Hoyos S, Otero-Romero S
    Author response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:456-457.
    PubMed    


  8. JOKUBAITIS VG, Dobson R
    Reader response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:455-456.
    PubMed    


  9. GANESH A, Galetta S
    Editors' note: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:455.
    PubMed    


  10. AMEZCUA L, Smith JB, Gonzales EG, Haraszti S, et al
    Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis.
    Neurology. 2020 Mar 9. pii: WNL.0000000000009210.
    PubMed     Abstract available



  11. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2020 Mar 2. pii: WNL.0000000000008670.
    PubMed    


    February 2020
  12. OBEIDAT AZ, Jassam YN, Hua LH, Cutter G, et al
    Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.
    Neurology. 2020 Feb 27. pii: WNL.0000000000009096.
    PubMed     Abstract available


  13. BRANDSTADTER R, Ayeni O, Krieger SC, Harel NY, et al
    Detection of subtle gait disturbance and future fall risk in early multiple sclerosis.
    Neurology. 2020 Feb 26. pii: WNL.0000000000008938.
    PubMed     Abstract available


  14. DELCOIGNE B, Manouchehrinia A, Barro C, Benkert P, et al
    Blood neurofilament light levels segregate treatment effects in multiple sclerosis.
    Neurology. 2020 Feb 11. pii: WNL.0000000000009097.
    PubMed     Abstract available


    January 2020
  15. HARTUNG DM, Johnston KA, Geddes J, Bourdette DN, et al
    Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis.
    Neurology. 2020 Jan 15. pii: WNL.0000000000008936.
    PubMed     Abstract available


  16. HARDING K, Zhu F, Alotaibi M, Duggan T, et al
    Multiple cause of death analysis in multiple sclerosis: A population-based study.
    Neurology. 2020 Jan 13. pii: WNL.0000000000008907.
    PubMed     Abstract available


  17. MARRIE RA, O'Mahony J, Maxwell C, Ling V, et al
    Increased mental health care use by mothers of children with multiple sclerosis.
    Neurology. 2020 Jan 9. pii: WNL.0000000000008871.
    PubMed     Abstract available


    December 2019
  18. ROTSTEIN DL, Marrie RA, Maxwell C, Gandhi S, et al
    MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada.
    Neurology. 2019;93:e2203-e2215.
    PubMed     Abstract available


    November 2019
  19. SAVRANSKY A, Rubstein A, Rios MH, Vergel SL, et al
    Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination.
    Neurology. 2019;93:e2065-e2073.
    PubMed     Abstract available


  20. M HARTUNG D, Alley L, A Johnston K, Bourdette DN, et al
    Qualitative study on the price of drugs for multiple sclerosis: Gaming the system.
    Neurology. 2019 Nov 25. pii: WNL.0000000000008653.
    PubMed     Abstract available


  21. MCKAY KA, Ernstsson O, Manouchehrinia A, Olsson T, et al
    Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.
    Neurology. 2019 Nov 15. pii: WNL.0000000000008667.
    PubMed     Abstract available


  22. WATERS P, Vincent A
    Myelin oligodendrocyte glycoprotein CSF testing needs testing.
    Neurology. 2019;93:871-872.
    PubMed    


  23. MARIOTTO S, Gajofatto A, Batzu L, Delogu R, et al
    Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Neurology. 2019;93:e1867-e1872.
    PubMed     Abstract available


  24. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
    Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Neurology. 2019;93:e1852-e1866.
    PubMed     Abstract available


  25. HUPPERTS R, Smolders J, Vieth R, Holmoy T, et al
    Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a.
    Neurology. 2019;93:e1906-e1916.
    PubMed     Abstract available


  26. BINZER S, McKay KA, Brenner P, Hillert J, et al
    Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2019 Nov 8. pii: WNL.0000000000008617.
    PubMed     Abstract available


    October 2019
  27. SORMANI MP, Naismith RT
    Measuring disability in multiple sclerosis: Walking plus much more.
    Neurology. 2019 Oct 22. pii: WNL.0000000000008515.
    PubMed    


  28. GOLDMAN MD, LaRocca NG, Rudick RA, Hudson LD, et al
    Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
    Neurology. 2019 Oct 22. pii: WNL.0000000000008519.
    PubMed     Abstract available



  29. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:769.
    PubMed    


  30. RAE-GRANT AD
    Author response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:765.
    PubMed    


  31. TRAN KR
    Reader response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:764-765.
    PubMed    


  32. GANESH A, Galetta S
    Editors' note: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:764.
    PubMed    


  33. VAN KEMPEN ZLE, Doesburg D, Dekker I, Lissenberg-Witte BI, et al
    The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms.
    Neurology. 2019;93:e1579-e1586.
    PubMed     Abstract available


  34. CLIFFORD DB, Tyler KL
    Dosing interval of natalizumab in MS: Do good things come to those who wait?
    Neurology. 2019;93:655-656.
    PubMed    


  35. RYERSON LZ, Foley J, Chang I, Kister I, et al
    Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
    Neurology. 2019;93:e1452-e1462.
    PubMed     Abstract available


  36. TUR C, Kalincik T, Oh J, Sormani MP, et al
    Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.
    Neurology. 2019 Oct 7. pii: WNL.0000000000008319.
    PubMed     Abstract available


    September 2019
  37. WATANABE M, Nakamura Y, Michalak Z, Isobe N, et al
    Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Neurology. 2019;93:e1299-e1311.
    PubMed     Abstract available


  38. PFUHL C, Grittner U, Giess RM, Scheel M, et al
    Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2019 Sep 9. pii: WNL.0000000000008237.
    PubMed     Abstract available


  39. EIJLERS AJC, Dekker I, Steenwijk MD, Meijer KA, et al
    Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008198.
    PubMed     Abstract available


  40. BARKHOF F, Kappos L, Wolinsky JS, Li DKB, et al
    Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008189.
    PubMed     Abstract available


  41. WONG YYM, Bruijstens AL, Barro C, Michalak Z, et al
    Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.
    Neurology. 2019;93:e968-e974.
    PubMed     Abstract available


    August 2019
  42. FAREZ MF, Correale J, Armstrong MJ, Rae-Grant A, et al
    Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019 Aug 28. pii: WNL.0000000000008157.
    PubMed     Abstract available


  43. YEH EA, Graves J
    Vaccination: Not a trigger for MS.
    Neurology. 2019;93:377-378.
    PubMed    


  44. SUMOWSKI JF, Muhlert N
    Dalfampridine improves slowed processing speed in MS: Picking up the pace.
    Neurology. 2019;93:325-326.
    PubMed    


  45. SECHI E, Keegan BM, Kaufmann TJ, Kantarci OH, et al
    Unilateral motor progression in MS: Association with a critical corticospinal tract lesion.
    Neurology. 2019;93:e628-e634.
    PubMed     Abstract available


  46. ZIVADINOV R, Bergsland N, Hagemeier J, Ramasamy DP, et al
    Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.
    Neurology. 2019;93:e611-e623.
    PubMed     Abstract available


  47. SNYDER J, Turner L
    Crowdfunding for stem cell-based interventions to treat neurologic diseases and injuries.
    Neurology. 2019;93:252-258.
    PubMed     Abstract available


    July 2019
  48. HAPFELMEIER A, Gasperi C, Donnachie E, Hemmer B, et al
    A large case-control study on vaccination as risk factor for multiple sclerosis.
    Neurology. 2019 Jul 30. pii: WNL.0000000000008012.
    PubMed     Abstract available


  49. MATEEN FJ
    Multiple sclerosis in resource-limited settings: Research opportunities in an unequal world.
    Neurology. 2019;93:176-180.
    PubMed     Abstract available


  50. DE GIGLIO L, De Luca F, Gurreri F, Ferrante I, et al
    Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
    Neurology. 2019 Jul 22. pii: WNL.0000000000007970.
    PubMed     Abstract available


  51. SCHMIDT M, Westemeier J, Gross D
    The two lives of neurologist Helmut J. Bauer (1914-2008): Renowned MS specialist and National Socialist.
    Neurology. 2019;93:109-113.
    PubMed     Abstract available


  52. LAPLAUD DA, Casey R, Barbin L, Debouverie M, et al
    Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
    Neurology. 2019 Jul 12. pii: WNL.0000000000007938.
    PubMed     Abstract available


  53. HERSH CM, Marrie RA
    Harnessing real-world data to inform treatment decisions in multiple sclerosis.
    Neurology. 2019 Jul 12. pii: WNL.0000000000007934.
    PubMed    


    May 2019
  54. WAUBANT E, Banwell B, Wassmer E, Sormani MP, et al
    Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.
    Neurology. 2019;92:e2538-e2549.
    PubMed     Abstract available


  55. MCKAY KA, Hillert J, Manouchehrinia A
    Long-term disability progression ofpediatric-onset multiple sclerosis.
    Neurology. 2019 May 15. pii: WNL.0000000000007647.
    PubMed     Abstract available


  56. PAPADOPOULOU A, Gaetano L, Pfister A, Altermatt A, et al
    Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.
    Neurology. 2019;92:e2240-e2249.
    PubMed     Abstract available


  57. BLANKENBACH K, Schwab N, Hofner B, Adams O, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
    Neurology. 2019;92:e2232-e2239.
    PubMed     Abstract available


  58. CALABRESE M, Gasperini C, Tortorella C, Schiavi G, et al
    "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study.
    Neurology. 2019 May 1. pii: WNL.0000000000007573.
    PubMed     Abstract available


  59. BROWNLEE WJ
    Differential diagnosis of multiple sclerosis: The better explanations in clinical practice.
    Neurology. 2019 May 1. pii: WNL.0000000000007566.
    PubMed    


    April 2019
  60. DI LUCA DG, De Leon-Benedetti A, Williamson S, Irving LT, et al
    Teaching Video NeuroImages: A patient with Holmes tremor due to demyelinating lesion of the inferior cerebellar peduncle.
    Neurology. 2019;92:e2179-e2180.
    PubMed    


  61. MAILLART E, Mochel F, Acquaviva C, Maisonobe T, et al
    Severe transient myopathy in a progressive multiple sclerosis patient with high-dose biotin.
    Neurology. 2019 Apr 26. pii: WNL.0000000000007576.
    PubMed    


  62. NIJ BIJVANK JA, van Rijn LJ, Balk LJ, Tan HS, et al
    Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.
    Neurology. 2019 Apr 19. pii: WNL.0000000000007499.
    PubMed     Abstract available


  63. VILLOSLADA P, Green AJ, Galetta S
    Personalizing medical care for MS patients: Monitoring brainstem damage by infrared oculography.
    Neurology. 2019 Apr 19. pii: WNL.0000000000007493.
    PubMed    


  64. BURON MD, Chalmer TA, Sellebjerg F, Frederiksen J, et al
    Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
    Neurology. 2019;92:e1811-e1820.
    PubMed     Abstract available


  65. MEHTA D, Miller C, Arnold DL, Bame E, et al
    Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Neurology. 2019;92:e1724-e1738.
    PubMed     Abstract available


  66. KILLESTEIN J, Reder AT
    Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring.
    Neurology. 2019;92:696-697.
    PubMed    


  67. WAUBANT E, Gilmore W
    Mind the gap: Quantifying gender representation as a first step to solve the problem?
    Neurology. 2019;92:698-699.
    PubMed    


  68. CORTESE M, Chitnis T, Ascherio A, Munger KL, et al
    Total intake of different minerals and the risk of multiple sclerosis.
    Neurology. 2019 Apr 3. pii: WNL.0000000000006800.
    PubMed     Abstract available


  69. MCDONNELL GV, Marriott JJ
    Patient-perceived risks of MS DMTs: Problems of communication and risk management?
    Neurology. 2019;92:647-648.
    PubMed    


  70. MARRIE RA, Garland A, Schaffer SA, Fransoo R, et al
    Traditional risk factors may not explain increased incidence of myocardial infarction in MS.
    Neurology. 2019;92:e1624-e1633.
    PubMed     Abstract available


    March 2019
  71. CONWAY DS
    What is the impact of socioeconomic status on multiple sclerosis?
    Neurology. 2019;92:e1536-e1539.
    PubMed    


  72. GORIS A, Dubois B
    Leveraging human genetics to inform intervention strategies for multiple sclerosis.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007298.
    PubMed    


  73. THOMSON A, Horne R, Chung C, Marta M, et al
    Visibility and representation of women in multiple sclerosis research.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007276.
    PubMed     Abstract available


  74. HARROUD A, Morris JA, Forgetta V, Mitchell R, et al
    Effect of age at puberty on risk of multiple sclerosis: A mendelian randomization study.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007325.
    PubMed     Abstract available


  75. KALINCIK T
    Effectiveness of oral multiple sclerosis therapies in clinical context.
    Neurology. 2019 Mar 15. pii: WNL.0000000000007300.
    PubMed    


  76. DE MEO E, Meani A, Moiola L, Ghezzi A, et al
    Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5-year MRI study.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007267.
    PubMed     Abstract available


  77. FOX RJ, Cosenza C, Cripps L, Ford P, et al
    A survey of risk tolerance to multiple sclerosis therapies.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007245.
    PubMed     Abstract available


  78. YEH EA, Eshaghi A
    Evolution of regional brain atrophy in children with multiple sclerosis: Gray matters.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007254.
    PubMed    


  79. BAR-OR A, Grove RA, Tolson JM, Derosier FJ, et al
    Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:543.
    PubMed    


  80. KEARNEY H
    Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542-543.
    PubMed    


  81. LEWIS A, Galetta S
    Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542.
    PubMed    


  82. WATERS PJ, Komorowski L, Woodhall M, Lederer S, et al
    A multicenter comparison of MOG-IgG cell-based assays.
    Neurology. 2019;92:e1250-e1255.
    PubMed     Abstract available


  83. LAPUCCI C, Saitta L, Bommarito G, Sormani MP, et al
    How much do periventricular lesions assist in distinguishing migraine with aura from CIS?
    Neurology. 2019 Mar 8. pii: WNL.0000000000007266.
    PubMed     Abstract available


  84. CULPEPPER WJ, Marrie RA, Langer-Gould A, Wallin MT, et al
    Validation of an algorithm for identifying MS cases in administrative health claims datasets.
    Neurology. 2019;92:e1016-e1028.
    PubMed     Abstract available


  85. WALLIN MT, Culpepper WJ, Campbell JD, Nelson LM, et al
    The prevalence of MS in the United States: A population-based estimate using health claims data.
    Neurology. 2019;92:e1029-e1040.
    PubMed     Abstract available


  86. KUHLE J, Kropshofer H, Haering DA, Kundu U, et al
    Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
    Neurology. 2019;92:e1007-e1015.
    PubMed     Abstract available


  87. ZULUAGA MI, Otero-Romero S, Rovira A, Perez-Hoyos S, et al
    Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2019 Mar 1. pii: WNL.0000000000007178.
    PubMed     Abstract available


    February 2019
  88. HARDING KE, Wardle M, Carruthers R, Robertson N, et al
    Socioeconomic status and disability progression in multiple sclerosis: A multinational study.
    Neurology. 2019 Feb 22. pii: WNL.0000000000007190.
    PubMed     Abstract available


  89. OH J, Ontaneda D, Azevedo C, Klawiter EC, et al
    Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.
    Neurology. 2019 Feb 20. pii: WNL.0000000000007099.
    PubMed     Abstract available


  90. KOCH-HENRIKSEN N
    Author response: Incidence of MS has increased markedly over 6 decades in Denmark particularly with late onset and in women.
    Neurology. 2019;92:397.
    PubMed    


  91. SAJEDI SA
    Reader response: Incidence of MS has increased markedly over 6 decades in Denmark particularly with late onset and in women.
    Neurology. 2019;92:397.
    PubMed    


  92. BENARROCH EE
    Autonomic nervous system and neuroimmune interactions: New insights and clinical implications.
    Neurology. 2019;92:377-385.
    PubMed    


  93. DALLA COSTA G, Martinelli V, Sangalli F, Moiola L, et al
    Prognostic value of serum neurofilaments in patients with clinically isolated syndromes.
    Neurology. 2019;92:e733-e741.
    PubMed     Abstract available


  94. BERGER T, Stuve O
    Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.
    Neurology. 2019 Feb 8. pii: WNL.0000000000007022.
    PubMed    


  95. XU SC, Kardon RH, Leavitt JA, Flanagan EP, et al
    Optical coherence tomography is highly sensitive in detecting prior optic neuritis.
    Neurology. 2019;92:e527-e535.
    PubMed     Abstract available


    January 2019
  96. BERGER JR, Cree BA, Greenberg B, Hemmer B, et al
    Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed    


  97. LALIVE PH, Roth S, Du Pasquier R
    Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed    


  98. ZETTERBERG H, Svenningsson A
    Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006906.
    PubMed    


  99. HONCE JM, Nair KV, Sillau S, Valdez B, et al
    Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006916.
    PubMed     Abstract available


  100. COHEN BA
    Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006924.
    PubMed    



  101. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:112.
    PubMed    


  102. RAE-GRANT A
    Author response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:110-111.
    PubMed    


  103. SALTONSTALL L
    Reader response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:109-110.
    PubMed    


  104. LEWIS A, Galetta S
    Editors' note: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:109.
    PubMed    


    December 2018
  105. PAPPOLLA A, Midaglia L, Boix Rodriguez CP, Puig AA, et al
    Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis.
    Neurology. 2018 Dec 26. pii: WNL.0000000000006801.
    PubMed    


  106. GASPERINI C, Prosperini L, Tintore M, Sormani MP, et al
    Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.
    Neurology. 2018 Dec 26. pii: WNL.0000000000006810.
    PubMed     Abstract available


    November 2018
  107. MARRIE RA, Butzkueven H, Ascherio A
    Obesity and brain volume loss in multiple sclerosis.
    Neurology. 2018 Nov 14. pii: WNL.0000000000006638.
    PubMed    


  108. RUCK T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, et al
    Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
    Neurology. 2018 Nov 7. pii: WNL.0000000000006648.
    PubMed     Abstract available


    October 2018
  109. BROWNLEE WJ
    Misdiagnosis of multiple sclerosis: If you have a hammer, everything looks like a nail?
    Neurology. 2018 Oct 31. pii: WNL.0000000000006584.
    PubMed    


  110. SOLOMON AJ, Naismith RT, Cross AH
    Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.
    Neurology. 2018 Oct 31. pii: WNL.0000000000006583.
    PubMed     Abstract available


  111. PORTACCIO E, Amato MP
    Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:851.
    PubMed    


  112. SOTGIU S, Eusebi A, Begliuomini C, Guerini FR, et al
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:850.
    PubMed    


  113. PROSCHMANN U, Akgun K, Ziemssen T
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849-850.
    PubMed    


  114. LEWIS A, Galetta S
    Editors' note: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849.
    PubMed    


  115. KRYSKO KM, Graves J, Rensel M, Weinstock-Guttman B, et al
    Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
    Neurology. 2018 Oct 17. pii: WNL.0000000000006471.
    PubMed     Abstract available


    September 2018
  116. CAVALLA P, Gilmore W
    Pregnancy in multiple sclerosis: Data from an administrative claims database.
    Neurology. 2018 Sep 28. pii: WNL.0000000000006371.
    PubMed    


  117. BAHEERATHAN A, McNamara C, Kalam S, Rane N, et al
    The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
    Neurology. 2018;91:572-573.
    PubMed    



  118. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018;91:538.
    PubMed    


    August 2018
  119. MIDAGLIA L, Gratacos M, Caronna E, Raguer N, et al
    Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006251.
    PubMed    


  120. BROWNLEE WJ, Miszkiel KA, Tur C, Barkhof F, et al
    Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis.
    Neurology. 2018 Aug 17. pii: WNL.0000000000006207.
    PubMed     Abstract available


    June 2018
  121. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Spinal cord volume loss: A marker of disease progression in multiple sclerosis.
    Neurology. 2018 Jun 27. pii: WNL.0000000000005853.
    PubMed     Abstract available


  122. PRADOS F, Barkhof F
    Spinal cord atrophy rates: Ready for prime time in multiple sclerosis clinical trials?
    Neurology. 2018 Jun 27. pii: WNL.0000000000005873.
    PubMed    


  123. HAGENS MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, et al
    Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.
    Neurology. 2018 Jun 20. pii: WNL.0000000000005825.
    PubMed     Abstract available


  124. PROSPERINI L, Lucchini M, Haggiag S, Bellantonio P, et al
    Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005772.
    PubMed     Abstract available


    May 2018
  125. LEHMANN HC, Compston A, Hartung HP
    150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy.
    Neurology. 2018;90:1011-1016.
    PubMed     Abstract available


  126. SCALFARI A, Romualdi C, Nicholas RS, Mattoscio M, et al
    The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.
    Neurology. 2018 May 16. pii: WNL.0000000000005685.
    PubMed     Abstract available


  127. FRANKLIN GM, McDonnell G
    Free health care, great data, and new clues on multiple sclerosis.
    Neurology. 2018 May 2. pii: WNL.0000000000005593.
    PubMed    


    April 2018
  128. GERARDI C, Bertele' V, Rossi S, Garattini S, et al
    Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005561.
    PubMed     Abstract available


  129. BAR-OR A, Grove RA, Austin DJ, Tolson JM, et al
    Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005516.
    PubMed     Abstract available


  130. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:789-800.
    PubMed     Abstract available


  131. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:777-788.
    PubMed     Abstract available


  132. CORREALE J, Ysrraelit MC, Benarroch EE
    Metabolic coupling of axons and glial cells: Implications for multiple sclerosis progression.
    Neurology. 2018;90:737-744.
    PubMed    


    March 2018
  133. FERRARO D, Camera V, Vitetta F, Zennaro M, et al
    Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005417.
    PubMed    


  134. SAARELA M, Senthil K, Jones J, Tienari PJ, et al
    Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005420.
    PubMed    


  135. ROTSTEIN DL, Chen H, Wilton AS, Kwong JC, et al
    Temporal trends in multiple sclerosis prevalence and incidence in a large population.
    Neurology. 2018 Mar 16. pii: WNL.0000000000005331.
    PubMed     Abstract available


  136. GAETANO L, Haring DA, Radue EW, Mueller-Lenke N, et al
    Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005292.
    PubMed     Abstract available


  137. SCHOONHEIM MM, Ciccarelli O
    The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005279.
    PubMed    


  138. MCKAY KA, Tremlett H, Fisk JD, Zhang T, et al
    Psychiatric comorbidity is associated with disability progression in multiple sclerosis.
    Neurology. 2018 Mar 9. pii: WNL.0000000000005302.
    PubMed     Abstract available


  139. MILLER AE, Calabresi PA
    Central vein sign in multiple sclerosis: Ready for front and center?
    Neurology. 2018 Mar 7. pii: WNL.0000000000005241.
    PubMed    


  140. TREMLETT H, Zhu F, Ascherio A, Munger KL, et al
    Sun exposure over the life course and associations with multiple sclerosis.
    Neurology. 2018 Mar 7. pii: WNL.0000000000005257.
    PubMed     Abstract available


    February 2018
  141. CHATAWAY J, Martin K, Barrell K, Sharrack B, et al
    Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005118.
    PubMed     Abstract available


  142. BATEMAN EM, Schleicher WE, Smith EJ, Sweet DR, et al
    Journal Club: MRI reveals acute inflammation in cortical lesions during early MS.
    Neurology. 2018;90:e724-e726.
    PubMed     Abstract available


  143. PORTACCIO E, Annovazzi P, Ghezzi A, Zaffaroni M, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005067.
    PubMed     Abstract available


  144. PORTACCIO E, Moiola L, Martinelli V, Annovazzi P, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005068.
    PubMed     Abstract available


  145. ALROUGHANI R, Alowayesh MS, Ahmed SF, Behbehani R, et al
    Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005065.
    PubMed     Abstract available


    January 2018
  146. BENNETT S, Leavitt VM
    An intervention to improve balance in persons with multiple sclerosis.
    Neurology. 2018 Jan 31. pii: WNL.0000000000005038.
    PubMed    


  147. HEBERT JR, Corboy JR, Vollmer T, Forster JE, et al
    Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS).
    Neurology. 2018 Jan 31. pii: WNL.0000000000005013.
    PubMed     Abstract available


  148. WEHRUM T, Beume LA, Stich O, Mader I, et al
    Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
    Neurology. 2018 Jan 19. pii: WNL.0000000000004950.
    PubMed     Abstract available


  149. PETERSEN ER, Oturai AB, Koch-Henriksen N, Magyari M, et al
    Smoking affects the interferon beta treatment response in multiple sclerosis.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004949.
    PubMed     Abstract available


  150. SUMOWSKI JF, Benedict R, Enzinger C, Filippi M, et al
    Cognition in multiple sclerosis: State of the field and priorities for the future.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004977.
    PubMed     Abstract available


  151. ZHANG T, Tremlett H, Zhu F, Kingwell E, et al
    Effects of physical comorbidities on disability progression in multiple sclerosis.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004885.
    PubMed     Abstract available


    December 2017
  152. PISA M, Guerrieri S, Di Maggio G, Medaglini S, et al
    No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS.
    Neurology. 2017;89:2469-2475.
    PubMed     Abstract available


  153. LOREFICE L, Fenu G, Gerevini S, Frau J, et al
    PML in a person with multiple sclerosis: Is teriflunomide the felon?
    Neurology. 2017 Dec 6. pii: WNL.0000000000004804.
    PubMed    


  154. FITZGERALD KC, Tyry T, Salter A, Cofield SS, et al
    Diet quality is associated with disability and symptom severity in multiple sclerosis.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004768.
    PubMed     Abstract available


  155. SUMOWSKI JF, McDonnell GV, Bourdette D
    Diet in multiple sclerosis: Science takes a seat at the table.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004775.
    PubMed    


    November 2017
  156. KARCESKI S
    How comorbid conditions affect the choice of treatment in multiple sclerosis.
    Neurology. 2017;89:e265-e267.
    PubMed    


  157. LARONI A, Signori A, Maniscalco GT, Lanzillo R, et al
    Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
    Neurology. 2017;89:2222-2229.
    PubMed     Abstract available


  158. KOWALEC K, McKay KA, Patten SB, Fisk JD, et al
    Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004716.
    PubMed     Abstract available


  159. BURMAN J, Zelano J
    Epilepsy in multiple sclerosis: A nationwide population-based register study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004740.
    PubMed     Abstract available


  160. ARRAMBIDE G, Tintore M, Auger C, Rio J, et al
    Lesion topographies in multiple sclerosis diagnosis: A reappraisal.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004715.
    PubMed     Abstract available


    October 2017
  161. NOVAKOVA L, Zetterberg H, Sundstrom P, Axelsson M, et al
    Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Neurology. 2017 Oct 27. pii: 10.1212/WNL.0000000000004683.
    PubMed     Abstract available


  162. CHIANG S, Kesari NK, Bradshaw A, Chen W, et al
    Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.
    Neurology. 2017;89:e210-e213.
    PubMed    


  163. TSIVGOULIS G, Papadimitropoulos GN, Katsanos AH, Zompola C, et al
    Teaching NeuroImages: Interferon-induced psoriasis flare in a multiple sclerosis case remits with dimethyl fumarate.
    Neurology. 2017;89:e188-e189.
    PubMed    


  164. MUNGER KL, Hongell K, Aivo J, Soilu-Hanninen M, et al
    25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.
    Neurology. 2017;89:1578-1583.
    PubMed     Abstract available


    September 2017
  165. KARCESKI S
    Multiple sclerosis, inflammation in the brain, and mood.
    Neurology. 2017;89:e169-e171.
    PubMed    


  166. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1429-1430.
    PubMed    


  167. SETHI NK
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis and Physician-assisted death in chronic neurologic diseases.
    Neurology. 2017;89:1429.
    PubMed    


  168. MASDEU JC
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1428.
    PubMed    


  169. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Abstract available


  170. PLAVINA T, Muralidharan KK, Kuesters G, Mikol D, et al
    Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Neurology. 2017 Sep 15. pii: 10.1212/WNL.0000000000004485.
    PubMed     Abstract available


  171. MARRIE RA, Beck CA
    Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D?
    Neurology. 2017 Sep 13. pii: 10.1212/WNL.0000000000004506.
    PubMed    


  172. FILLI L, Zorner B, Killeen T, Linnebank M, et al
    Author response: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1200.
    PubMed    


  173. DAVIS FA
    Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1199.
    PubMed    


  174. COLES AJ, Cohen JA, Fox EJ, Giovannoni G, et al
    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Neurology. 2017;89:1117-1126.
    PubMed     Abstract available


  175. HAVRDOVA E, Arnold DL, Cohen JA, Hartung HP, et al
    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Neurology. 2017;89:1107-1116.
    PubMed     Abstract available


  176. LORSCHEIDER J, Jokubaitis VG, Spelman T, Izquierdo G, et al
    Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Neurology. 2017;89:1050-1059.
    PubMed     Abstract available


    August 2017
  177. LANGER-GOULD A, Wu J, Lucas R, Smith J, et al
    Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004412.
    PubMed     Abstract available


  178. HENNES EM, Baumann M, Schanda K, Anlar B, et al
    Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Neurology. 2017;89:900-908.
    PubMed     Abstract available


  179. ROSSI S, Studer V, Motta C, Polidoro S, et al
    Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004411.
    PubMed     Abstract available


  180. KOCH-HENRIKSEN N, Lauer K
    Dietary sodium intake: An etiologic dead end in multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004426.
    PubMed    


  181. CORTESE M, Yuan C, Chitnis T, Ascherio A, et al
    No association between dietary sodium intake and the risk of multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004417.
    PubMed     Abstract available


  182. WIENDL H, Bourdette D, Ciccarelli O
    Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004381.
    PubMed    


  183. DE MEO E, Moiola L, Ghezzi A, Veggiotti P, et al
    MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004388.
    PubMed     Abstract available



  184. Escalation therapy for multiple sclerosis in Austria: Analysis of gender differences in the nationwide registry.
    Neurology. 2017;89:752.
    PubMed    


    July 2017
  185. NIELSEN NM, Munger KL, Stenager E, Ascherio A, et al
    Author response: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:411.
    PubMed    


  186. XIA Z, Cheng Q, Li J
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410-411.
    PubMed    


  187. ZARGHAMI A
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410.
    PubMed    


  188. MARANZANO J, Rudko DA, Nakamura K, Cook S, et al
    MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004227.
    PubMed     Abstract available


  189. HACOHEN Y, Mankad K, Chong WK, Barkhof F, et al
    Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Neurology. 2017;89:269-278.
    PubMed     Abstract available


  190. LANGER-GOULD A, Smith JB, Hellwig K, Gonzales E, et al
    Breastfeeding, ovulatory years, and risk of multiple sclerosis.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004207.
    PubMed     Abstract available



  191. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017;89:215.
    PubMed    


  192. BURKILL S, Montgomery S, Hajiebrahimi M, Hillert J, et al
    Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.
    Neurology. 2017 Jul 7. pii: 10.1212/WNL.0000000000004216.
    PubMed     Abstract available


    June 2017
  193. DE JONG HJI, Kingwell E, Shirani A, Cohen Tervaert JW, et al
    Evaluating the safety of beta-interferons in MS: A series of nested case-control studies.
    Neurology. 2017;88:2310-2320.
    PubMed     Abstract available


    May 2017
  194. BATISTA S, Alves C, d'Almeida OC, Afonso A, et al
    Disconnection as a mechanism for social cognition impairment in multiple sclerosis.
    Neurology. 2017 May 31. pii: 10.1212/WNL.0000000000004060.
    PubMed     Abstract available


  195. SOLOMON AJ, Weinshenker BG
    Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067-2068.
    PubMed    


  196. DALLA COSTA G, Martinelli V, Comi G
    Letter re: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067.
    PubMed    


  197. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed    


  198. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed    


  199. MEIJER KA, Eijlers AJC, Douw L, Uitdehaag BMJ, et al
    Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003982.
    PubMed     Abstract available


    April 2017
  200. SORMANI MP, Muraro PA, Schiavetti I, Signori A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987.
    PubMed     Abstract available


  201. GIANFRANCESCO MA, Stridh P, Rhead B, Shao X, et al
    Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.
    Neurology. 2017;88:1623-1629.
    PubMed     Abstract available


    March 2017
  202. LANDI D, De Rossi N, Zagaglia S, Scarpazza C, et al
    No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Neurology. 2017;88:1144-1152.
    PubMed     Abstract available


  203. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003831.
    PubMed     Abstract available


  204. ABSINTA M, Cortese IC, Vuolo L, Nair G, et al
    Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003820.
    PubMed     Abstract available


    February 2017
  205. NASH RA, Hutton GJ, Racke MK, Popat U, et al
    High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Neurology. 2017;88:842-852.
    PubMed     Abstract available


  206. KUHLE J, Nourbakhsh B, Grant D, Morant S, et al
    Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology. 2017;88:826-831.
    PubMed     Abstract available


  207. SIDHOM Y, Maillart E, Tezenas du Montcel S, Kacem I, et al
    Fast multiple sclerosis progression in North Africans: Both genetics and environment matter.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003762.
    PubMed     Abstract available


  208. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed    


  209. EIJLERS AJ, Meijer KA, Wassenaar TM, Steenwijk MD, et al
    Increased default-mode network centrality in cognitively impaired multiple sclerosis patients.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003689.
    PubMed     Abstract available


  210. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed    


  211. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed    


  212. FILLI L, Zorner B, Kapitza S, Reuter K, et al
    Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003656.
    PubMed     Abstract available


  213. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed    


    January 2017
  214. MAAROUF A, Audoin B, Pariollaud F, Gherib S, et al
    Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.
    Neurology. 2017;88:289-295.
    PubMed     Abstract available


  215. BARGIELA D, Bianchi MT, Westover MB, Chibnik LB, et al
    Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
    Neurology. 2017 Jan 13. pii: 10.1212/WNL.0000000000003612.
    PubMed     Abstract available


  216. BUTTON J, Al-Louzi O, Lang A, Bhargava P, et al
    Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Neurology. 2017 Jan 11. pii: 10.1212/WNL.0000000000003582.
    PubMed     Abstract available


    December 2016
  217. ROCCA MA, Battaglini M, Benedict RH, De Stefano N, et al
    Brain MRI atrophy quantification in MS: From methods to clinical application.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003542.
    PubMed     Abstract available


    November 2016
  218. NIELSEN NM, Munger KL, Koch-Henriksen N, Hougaard DM, et al
    Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003454.
    PubMed     Abstract available


  219. TENSER RB, Truini A, Cruccu G
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016;87:2385-2386.
    PubMed    



  220. Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:2284.
    PubMed    


  221. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed    



  222. Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87:2068.
    PubMed    


  223. ESHAGHI A, Wottschel V, Cortese R, Calabrese M, et al
    Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2016 Nov 2. pii: 10.1212/WNL.0000000000003395.
    PubMed     Abstract available


    October 2016
  224. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed    


  225. SALZER J, Svenningsson R, Alping P, Novakova L, et al
    Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003331.
    PubMed     Abstract available


  226. GIOVANNONI G, Cohen JA, Coles AJ, Hartung HP, et al
    Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003319.
    PubMed     Abstract available


    September 2016
  227. DORANS KS, Massa J, Chitnis T, Ascherio A, et al
    Physical activity and the incidence of multiple sclerosis.
    Neurology. 2016 Sep 28. pii: 10.1212/WNL.0000000000003260.
    PubMed     Abstract available


  228. KANTOR D, Sotirchos ES, Calabresi PA
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:1424.
    PubMed    


  229. COTTER J, Firth J, Enzinger C, Kontopantelis E, et al
    Social cognition in multiple sclerosis: A systematic review and meta-analysis.
    Neurology. 2016 Sep 21. pii: 10.1212/WNL.0000000000003236.
    PubMed     Abstract available


  230. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed    


  231. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Abstract available


    July 2016
  232. BROWNLEE WJ, Swanton JK, Miszkiel KA, Miller DH, et al
    Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002975.
    PubMed     Abstract available


    April 2016
  233. DE LOTT LB, Burke JF, Kerber KA, Skolarus LE, et al
    Medicare Part D payments for neurologist-prescribed drugs.
    Neurology. 2016;86:1491-8.
    PubMed     Abstract available


    March 2016
  234. HODEL J, Darchis C, Outteryck O, Verclytte S, et al
    Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002586.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: